Clinical Research
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 21, 2006; 12(11): 1730-1738
Published online Mar 21, 2006. doi: 10.3748/wjg.v12.i11.1730
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 eNOS content in HUVEC treated with IBD sera (Western blot. Mean ± SE, n = 3; bP<0.01 vs normal).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 eNOS in HUVEC (immunoreaction was visualized by FITC. bar: 10 µm).
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 iNOS content in HUVEC (Western blot. Mean ± SE, n=3; bP<0.01 vs normal).
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 iNOS in HUVEC (immunoreaction was visualized by FITC. bar: 10 µm).
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Proliferation activity of HUVEC (Ki-67 immunoreactivity was visualized by FITC. bar: 50 µm. mean ± SE, n = 3; bP<0.01 vs normal).
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 HUVEC viability. A: Early apoptotic cells; B: necrotic cells; C: Late apoptotic cell; D: Phalloidin conjugated with TRITC labeled actin filaments. bars: 10 µm.
Figure 7
Open in New Tab Full Size Figure Download Figure
Figure 7 HUVEC 48 h incubation with CD sera (mean ± SE, n = 3).
Figure 8
Open in New Tab Full Size Figure Download Figure
Figure 8 HUVEC visualized by eNOS immunofluorescence in culture. bar: 50 µm.